Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index; 39 of the 66 sources its claims cite were checked for support.

Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review

Open access
Chen, Sixuan, Tu, Liping, Chen, Quanhua · 2026 · Frontiers in Pharmacology

Abstract

The field of spatial pharmacology has emerged as a critical framework for understanding the complex interactions between anti-cancer immunomodulators, tumor cells, and the tumor microenvironment (TME) at single-cell resolution. This review synthesizes the theoretical foundations, historical evolution, clinical applications, diagnostic techniques, therapeutic strategies, and future directions of spatial pharmacology in cancer immunotherapy. By integrating single-cell analysis, signaling dynamics, and multimodal approaches, spatial pharmacology addresses the limitations of traditional "one-size-fits-all" therapies by accounting for intratumoral heterogeneity, drug target accessibility, and immune cell spatial organization. Key advancements include single-cell RNA sequencing (scRNA-seq) for mapping drug target pathway activation, imaging techniques for visualizing signaling dynamics, and multimodal diagnostics for personalized treatment design. Clinical applications range from optimizing combinatorial regimens in metastatic renal cell carcinoma to predicting immunotherapy response in triple-negative breast cancer. Despite challenges such as overcoming drug resistance and enhancing target accessibility, emerging technologies like spatial transcriptomics and artificial intelligence (AI)-driven multi-omics integration promise to revolutionize precision oncology. This review highlights how spatial pharmacology is transforming cancer immunotherapy by enabling tailored interventions that account for the spatial and temporal complexity of tumor-immune interactions.

Overview

CoChat Summary

TL;DR

This review synthesizes spatial pharmacology for anti-cancer immunomodulators, integrating single-cell analysis, imaging, spatial transcriptomics, and AI to map drug-target engagement and immune signaling in the tumor microenvironment. It argues that intratumoral spatial and single-cell heterogeneity drives variable drug accessibility, resistance, and immunotherapy response, motivating multimodal, spatially resolved precision strategies.

Key findings

  • Single-cell and spatial heterogeneity affects every step of drug action: BTK and PARP inhibitors show variable target occupancy despite high average engagement; doxorubicin-chromatin binding varies between metastases and regions; intranuclear drug diffusion is three orders of magnitude slower than in vitro.
  • Target expression and accessibility are heterogeneous: glioblastoma integrin αvβ3 surface density ranges from 0 to 1.6 molecules per μm² and correlates with integrin-inhibitor sensitivity; renal cell carcinoma markers SPOCK1, PTGIS, and REG1A vary across subpopulations and pathological types; TRIPODD shows drug target availability is not always correlated with protein expression.
  • Clinical and translational examples include scRNA-seq-guided combinatorial regimens in metastatic renal cell carcinoma that improved efficacy in patient-derived xenograft models; entinostat in relapsed/refractory Hodgkin lymphoma with a 24% disease control rate and tumor reduction in 58% of evaluable patients; DBCSMOTE predicting warfarin dose within 20% in 47.8% of cases; and rituximab binding varying with up to 1200 radionuclides per cell.
  • Therapeutic strategies include co-targeting pathways (e.g., AURK/CDK/EGFR in glioblastoma; RAF/MEK/ERK in BRAF V600E-mutant cancer, effective in 11 of 11 patient-derived xenografts) and enhancing delivery (iRGD, T-DM1, losartan, pH/redox-responsive nanoparticles); future directions include spatial transcriptomics, AI-driven multi-omics, neoantigen vaccines, and biomarkers such as spatial immune infiltration and TCR clonality.

Methods

  • Design: comprehensive narrative review of spatial pharmacology in cancer immunotherapy, covering theoretical foundations, historical evolution, clinical practice, diagnostic techniques, therapeutic strategies, and future directions.
  • Evidence base: synthesizes cited preclinical and clinical studies using scRNA-seq, scATAC-seq, mass spectrometry imaging, fluorescence imaging, spatial transcriptomics, AI/multimodal models, and organoid or microfluidic models.
  • Analysis: narrative synthesis with conceptual figures, including a hierarchical framework in Figure 2; no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described.

Limitations

  • The review does not state formal limitations of its own methodology; it states field challenges including drug resistance, target accessibility, and limitations of current biomarkers such as PD-L1, tumor mutation burden, and microsatellite instability.
  • Evident from the text: as a narrative review, it lacks systematic search and selection methods and quantitative synthesis, so conclusions depend on the cited literature.
  • Evident from the text: examples include non-oncologic or non-immunomodulator contexts (e.g., retinal vein occlusion, atherosclerosis, neuropsychiatric signaling, cardiac repair), which may limit direct generalizability to anti-cancer immunomodulation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fphar.2026.1898418

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

FIGURE 1 Multidimensional characteristics of single-cell tumor heterogeneity that act as critical barriers to effective cancer therapy. (A) Encapsulates a fundamental observation: even when a tumor cell population shows high average target occupancy (as seen with BTK inhibitors), striking single-cell variability remains, with a subset of cells maintaining low target engagement that enables treatment evasion. (B) Illustrates the spatial heterogeneity of in vivo drug-chromatin interactions, demonstrating that doxorubicin-chromatin binding differs substantially not only between distinct metastatic lesions in the same animal but also across regional subregions within a single metastasis. This panel also depicts the markedly slowed kinetics of intranuclear drug diffusion-three orders of magnitude slower than in vitro-which drives near-irreversible target binding and further amplifies intercellular differences in intracellular drug exposure. (C) Summarizes heterogeneous expression of cell-surface targets and tumor-specific molecular markers: in glioblastoma, integrin α v β 3 surface density ranges widely and correlates directly with cellular sensitivity to integrin inhibitors; in renal cell carcinoma, the subtype-specific markers SPOCK1, PTGIS, and REG1A are differentially expressed across cell subpopulations, contributing to divergent drug responses across pathological subtypes. (D) Introduces the TRIPODD multimodal imaging platform, which integrates intracellular paired-agent imaging (iPAI) for drug quantification and cyclic immunofluorescence (cyCIF) for protein profiling to simultaneously measure drug target availability and protein expression at single-cell resolution.
FIGURE 1 Multidimensional characteristics of single-cell tumor heterogeneity that act as critical barriers to effective cancer therapy. (A) Encapsulates a fundamental observation: even when a tumor cell population shows high average target occupancy (as seen with BTK inhibitors), striking single-cell variability remains, with a subset of cells maintaining low target engagement that enables treatment evasion. (B) Illustrates the spatial heterogeneity of in vivo drug-chromatin interactions, demonstrating that doxorubicin-chromatin binding differs substantially not only between distinct metastatic lesions in the same animal but also across regional subregions within a single metastasis. This panel also depicts the markedly slowed kinetics of intranuclear drug diffusion-three orders of magnitude slower than in vitro-which drives near-irreversible target binding and further amplifies intercellular differences in intracellular drug exposure. (C) Summarizes heterogeneous expression of cell-surface targets and tumor-specific molecular markers: in glioblastoma, integrin α v β 3 surface density ranges widely and correlates directly with cellular sensitivity to integrin inhibitors; in renal cell carcinoma, the subtype-specific markers SPOCK1, PTGIS, and REG1A are differentially expressed across cell subpopulations, contributing to divergent drug responses across pathological subtypes. (D) Introduces the TRIPODD multimodal imaging platform, which integrates intracellular paired-agent imaging (iPAI) for drug quantification and cyclic immunofluorescence (cyCIF) for protein profiling to simultaneously measure drug target availability and protein expression at single-cell resolution.CC BY · From the PDF
Image 2
CC BY · From the PDF
Image 3
CC BY · From the PDF

Verification

Claims the paper makes

38 Valid · 1 Not valid · 28 Not checked · 11 Own results and interpretations

40 more claims · 22 with their cited sources checked

Create a free account to see all 78 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 28
  • Probably not a substantial claim. 6

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 72 references

Metadata

Authors
Chen, S., Tu, L., & Chen, Q.
Affiliations
  • Minxi Vocational & Technical College (CN)
  • Xiamen Medical College (CN)
Corresponding author
Chen, Quanhua
Venue
Frontiers in Pharmacology
Published
2026-08-12
Volume
17
Pages
1898418-1898418
ISSN
1663-9812 (ISSN-L)
OpenAlex
W7202254797
Cited by
1
References
72
Citations by year
2026: 1
FWCI
0.92
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Pharmacology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
tumor microenvironment, cancer immunotherapy, intratumoral heterogeneity, single-cell RNA sequencing, spatial transcriptomics, multimodal diagnostics, precision oncology, drug resistance, renal cell carcinoma, triple-negative breast cancer, immunotherapy response prediction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review. https://app.cochat.ai/papers/10.3389/fphar.2026.1898418
The paper
Chen, S., Tu, L., & Chen, Q. (2026). Spatial pharmacology of anti-cancer immunomodulators: a comprehensive review. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1898418

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.